Yong He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yong He has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
Ningning Ma
10 shared publicationsYingfen Chen
Department of Gastroenterology, Huadong Hospital, Fudan University, Shanghai, China
9 shared publicationsYawen Hao
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China
8 shared publicationsPeng Xiao
Department of Hepatology, The First Hospital of Jilin University, Changchun, China
6 shared publicationsQiuhong Zai
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China
6 shared publicationsRu Ya
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China
5 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (11) , 7165-7183
Molecular smugglers in obesity-driven MASLD: Snitching on adipose-derived extracellular vesicles
- 2 September 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (11) , 7165-7183
Open AccessMolecular smugglers in obesity-driven MASLD: Snitching on adipose-derived extracellular vesicles
- Open Access
- 30 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (18)
ITGBL1-MYH9 interaction in hepatic stellate cells acts as a mechanoregulator controlling liver fibrosis in mice
Hepatic stellate cell (HSC) activation can lead to liver fibrosis, for which there are no effective treatments. Aberrant cytoskeletal reorganization is a central driver of HSC activation. Non-muscle myosin II (NM II) is known to regulate cytoskeleton remodeling via its actin cross-linking and contractile properties. However, the molecular players controlling actomyosin assembly and contractility in HSCs during liver fibrosis remain poorly defined. Here, we identified integrin β-like 1 (ITGBL1) as a gatekeeper of HSC quiescence by negatively regulating actomyosin contractility-driven mechanotransduction in HSCs. ITGBL1 expression was markedly elevated in activated HSCs found in patient and mouse fibrotic livers. Unexpectedly, HSC-specific Itgbl1 deficiency worsened liver fibrosis, whereas ITGBL1 overexpression in HSCs limited it, suggesting a protective role for ITGBL1 against a pathogenic HSC activation. Multiomics and functional analyses revealed that ITGBL1 impaired F-actin filament organization in HSCs by disrupting actomyosin assembly dependent on myosin heavy chain 9 (MYH9, also named NM II heavy chain A). In line, HSC-specific Myh9 deficiency or silencing of Myh9 in HSCs alleviated liver fibrosis. Taken together, our findings unveil that ITGBL1-MYH9 interaction acts as a critical mechanoregulatory brake that maintains cytoskeletal equilibrium and mechanical homeostasis in HSCs, providing a promising therapeutic strategy to combat liver fibrosis.
- 30 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (18)
Open AccessITGBL1-MYH9 interaction in hepatic stellate cells acts as a mechanoregulator controlling liver fibrosis in mice
Hepatic stellate cell (HSC) activation can lead to liver fibrosis, for which there are no effective treatments. Aberrant cytoskeletal reorganization is a central driver of HSC activation. Non-muscle myosin II (NM II) is known to regulate cytoskeleton remodeling via its actin cross-linking and contractile properties. However, the molecular players controlling actomyosin assembly and contractility in HSCs during liver fibrosis remain poorly defined. Here, we identified integrin β-like 1 (ITGBL1) as a gatekeeper of HSC quiescence by negatively regulating actomyosin contractility-driven mechanotransduction in HSCs. ITGBL1 expression was markedly elevated in activated HSCs found in patient and mouse fibrotic livers. Unexpectedly, HSC-specific Itgbl1 deficiency worsened liver fibrosis, whereas ITGBL1 overexpression in HSCs limited it, suggesting a protective role for ITGBL1 against a pathogenic HSC activation. Multiomics and functional analyses revealed that ITGBL1 impaired F-actin filament organization in HSCs by disrupting actomyosin assembly dependent on myosin heavy chain 9 (MYH9, also named NM II heavy chain A). In line, HSC-specific Myh9 deficiency or silencing of Myh9 in HSCs alleviated liver fibrosis. Taken together, our findings unveil that ITGBL1-MYH9 interaction acts as a critical mechanoregulatory brake that maintains cytoskeletal equilibrium and mechanical homeostasis in HSCs, providing a promising therapeutic strategy to combat liver fibrosis.
- 18 June 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (5) , 868-881
Interleukin-19 ameliorates drug-induced liver injury by limiting proinflammatory macrophage infiltration via SUMOylation of C/EBPβ
- 18 June 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (5) , 868-881
Interleukin-19 ameliorates drug-induced liver injury by limiting proinflammatory macrophage infiltration via SUMOylation of C/EBPβ
- Open Access
- 24 April 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (8) , 101869
ANXA1-FPR1 signaling in myeloid cells drives MASH by elevating S100A4/A11
- 24 April 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (8) , 101869
Open AccessANXA1-FPR1 signaling in myeloid cells drives MASH by elevating S100A4/A11
- Open Access
- 9 April 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (11)
Sinusoidal endothelial cells control liver inflammation and fibrosis
Liver fibrosis is a common pathological outcome of chronic liver disease and is driven by inflammatory responses. However, the early signals that initiate the inflammatory cascade remain poorly understood. Emerging evidence suggests that liver sinusoidal endothelial cells (LSECs) are not merely passive bystanders, but active regulators during liver fibrosis. In this issue of the JCI , Gan et al. demonstrated in multiple preclinical models that BRD4/PML-mediated super-enhancer activation in LSECs drives proinflammatory angiocrine signaling, thereby initiating liver fibrosis. Thus, targeting this endothelial axis may offer a promising therapeutic strategy for the treatment of liver fibrosis.
- 9 April 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (11)
Open AccessSinusoidal endothelial cells control liver inflammation and fibrosis
Liver fibrosis is a common pathological outcome of chronic liver disease and is driven by inflammatory responses. However, the early signals that initiate the inflammatory cascade remain poorly understood. Emerging evidence suggests that liver sinusoidal endothelial cells (LSECs) are not merely passive bystanders, but active regulators during liver fibrosis. In this issue of the JCI , Gan et al. demonstrated in multiple preclinical models that BRD4/PML-mediated super-enhancer activation in LSECs drives proinflammatory angiocrine signaling, thereby initiating liver fibrosis. Thus, targeting this endothelial axis may offer a promising therapeutic strategy for the treatment of liver fibrosis.
- Open Access
- 17 March 2026
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 22 (7) , 3304-3321
Macrophage NEDD4L restrains liver fibrosis by preventing scar-associated macrophage expansion via ubiquitination of phospho-SMAD3
Background: Liver fibrosis is characterized by excessive extracellular matrix deposition and hepatic stellate cell (HSC) activation, driven by chronic liver injury and inflammation. Macrophages play dual roles in fibrogenesis; the dynamic balance between pro-fibrotic and anti-fibrotic subsets is critical in determining the progression or regression of the disease. NEDD4L, an E3 ubiquitin ligase, is well-known to be involved in cell biological processes by promoting protein degradation, yet its role in macrophages and liver fibrosis remains poorly understood.
- 17 March 2026
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 22 (7) , 3304-3321
Open AccessMacrophage NEDD4L restrains liver fibrosis by preventing scar-associated macrophage expansion via ubiquitination of phospho-SMAD3
Background: Liver fibrosis is characterized by excessive extracellular matrix deposition and hepatic stellate cell (HSC) activation, driven by chronic liver injury and inflammation. Macrophages play dual roles in fibrogenesis; the dynamic balance between pro-fibrotic and anti-fibrotic subsets is critical in determining the progression or regression of the disease. NEDD4L, an E3 ubiquitin ligase, is well-known to be involved in cell biological processes by promoting protein degradation, yet its role in macrophages and liver fibrosis remains poorly understood.
- Open Access
- 17 March 2026
- Published by Wiley in iNew Medicine
- Vol. 2 (2) , e70036
N 6 ‐Methyladenosine (m 6 A) in Liver Disease: Pathogenic Mechanisms and Therapeutic Potential
Accumulating evidence highlights the critical role of epigenetic modifications, particularly N 6 ‐methyladenosine (m 6 A), in liver disease. As the most abundant RNA modification in eukaryotic cells, m 6 A is dynamically regulated by multicomponent m 6 A methyltransferases (e.g., METTL3 and METTL14), demethylases (FTO and ALKBH5), and m 6 A‐binding proteins (YTHDF1/2/3, YTHDC1/2, and IGF2BP1/2/3). Recent studies have revealed the pivotal involvement of m 6 A and its regulators in a wide range of physiological and pathological processes in liver disease, including metabolic dysfunction‐associated steatotic liver disease (MASLD), liver fibrosis, hepatocellular carcinoma (HCC), as well as liver injury and regeneration. In this review, we summarize recent advances in understanding the emerging roles of m 6 A modifications in liver disease and discuss their potential as therapeutic targets, offering new perspectives for treating liver disease.
- 17 March 2026
- Published by Wiley in iNew Medicine
- Vol. 2 (2) , e70036
Open AccessN 6 ‐Methyladenosine (m 6 A) in Liver Disease: Pathogenic Mechanisms and Therapeutic Potential
Accumulating evidence highlights the critical role of epigenetic modifications, particularly N 6 ‐methyladenosine (m 6 A), in liver disease. As the most abundant RNA modification in eukaryotic cells, m 6 A is dynamically regulated by multicomponent m 6 A methyltransferases (e.g., METTL3 and METTL14), demethylases (FTO and ALKBH5), and m 6 A‐binding proteins (YTHDF1/2/3, YTHDC1/2, and IGF2BP1/2/3). Recent studies have revealed the pivotal involvement of m 6 A and its regulators in a wide range of physiological and pathological processes in liver disease, including metabolic dysfunction‐associated steatotic liver disease (MASLD), liver fibrosis, hepatocellular carcinoma (HCC), as well as liver injury and regeneration. In this review, we summarize recent advances in understanding the emerging roles of m 6 A modifications in liver disease and discuss their potential as therapeutic targets, offering new perspectives for treating liver disease.
- 10 October 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 84 (2) , 251-253
Alcohol consumption potentiates second-hit events in HBV-induced hepatocellular carcinoma
- 10 October 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 84 (2) , 251-253
Alcohol consumption potentiates second-hit events in HBV-induced hepatocellular carcinoma
- Top Cited PapersOpen Access
- 1 October 2025
- Published by BMJ in eGastroenterology
- Vol. 3 (4) , e100319
Metabolic dysfunction and alcohol-associated liver disease (MetALD)
Metabolic dysfunction and alcohol-associated liver disease (MetALD) is a recently implemented nomenclature and disease terminology for patients with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol. MetALD is diagnosed in individuals who have at least one metabolic risk factor (such as obesity, type 2 diabetes mellitus, hypertension, etc) and consume 140–350 g/week of alcohol for women or 210–420 g/week for men. Conversely, alcohol-associated liver disease is diagnosed in individuals who consume >350 g/week of alcohol for women and >420 g/week for men. MetALD represents a heterogeneous spectrum of liver disease, with variations in clinical presentation and severity driven by differences in metabolic profiles, drinking patterns and individual susceptibility. Alcohol and metabolic risk factors are thought to act synergistically to accelerate steatohepatitis, fibrosis and hepatocellular carcinoma. However, the precise mechanisms underlying liver injury in MetALD still remain poorly understood. In this comprehensive review, we summarise the current definition, diagnostic criteria and clinical management of MetALD. We also discuss emerging insights into understanding its pathogenesis, examine relevant experimental models and highlight future challenges and research priorities in this evolving field.
- 1 October 2025
- Published by BMJ in eGastroenterology
- Vol. 3 (4) , e100319
Top Cited PapersOpen AccessMetabolic dysfunction and alcohol-associated liver disease (MetALD)
Metabolic dysfunction and alcohol-associated liver disease (MetALD) is a recently implemented nomenclature and disease terminology for patients with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol. MetALD is diagnosed in individuals who have at least one metabolic risk factor (such as obesity, type 2 diabetes mellitus, hypertension, etc) and consume 140–350 g/week of alcohol for women or 210–420 g/week for men. Conversely, alcohol-associated liver disease is diagnosed in individuals who consume >350 g/week of alcohol for women and >420 g/week for men. MetALD represents a heterogeneous spectrum of liver disease, with variations in clinical presentation and severity driven by differences in metabolic profiles, drinking patterns and individual susceptibility. Alcohol and metabolic risk factors are thought to act synergistically to accelerate steatohepatitis, fibrosis and hepatocellular carcinoma. However, the precise mechanisms underlying liver injury in MetALD still remain poorly understood. In this comprehensive review, we summarise the current definition, diagnostic criteria and clinical management of MetALD. We also discuss emerging insights into understanding its pathogenesis, examine relevant experimental models and highlight future challenges and research priorities in this evolving field.
- Top Cited PapersOpen Access
- 4 September 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (11) , 5515-5536
Intestinal barrier in chronic gut and liver diseases: Pathogenesis and therapeutic targets
- 4 September 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (11) , 5515-5536
Top Cited PapersOpen AccessIntestinal barrier in chronic gut and liver diseases: Pathogenesis and therapeutic targets